Bethesda, MDNCT01631617Now EnrollingIRB Ready

Eczema Clinical Trial in Bethesda, MD

Access cutting-edge eczema treatment through this clinical trial at a research site in Bethesda. Study-provided care at no cost to qualified participants.

Sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Quick Self-Assessment

See if you qualify for this Bethesda location

Preparing your pre-screening questions…

Expert Care in Bethesda

Access eczema specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related eczema treatment provided free

Apply for This Bethesda Location

Check if you qualify for this eczema clinical trial in Bethesda, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Bethesda

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Bethesda site if eligible
  4. 4Begin participation

About This Eczema Study in Bethesda

Background: \- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria. Researchers want to study how eczema treatments affect the number and the type of bacteria on the skin. Objectives: \- To study the effect of eczema treatments on skin bacteria. Eligibility: * Individuals between 2 and 25 years of age who have moderate to severe atopic dermatitis. * Healthy volunteers between 18 and 40 years of age with no history of eczema. Design: * Participants will be screened with a physical exam and medical history. Research samples will be collected. Skin biopsies may also be performed. * All participants will be assigned to one of several study groups. * Healthy volunteers must not have taken antibiotics in the year before the start of the study. * All participants will have regular study visits during their 1-year participation. More research samples will be collected at these visits. * Healthy volunteers may be asked to come in for a one-time follow up after the 1 year mark.

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Who Can Participate

Inclusion Criteria

Cohorts 1 \[NO FURTHER ACCRUAL\], 2 \[INACTIVE\], 4 \[NO FURTHER ACCRUAL\] and 5 \[INACTIVE\]: Healthy Volunteers
Males and females aged 18-50 years at time of initial protocol sampling
Subjects must participate fully and be willing to comply with the procedures of the protocol
Subjects must be co-enrolled in NIH protocol 08-HG-0059
Ability of subject to understand and provide written informed consent
Access to bathing facilities (Cohort 2 \[INACTIVE\])
Ability to swallow capsules or tablets Cohort 3 \[INACTIVE\]: Atopic Dermatitis Patients
Subjects must be aged 2-50 years
Subjects must be co-enrolled in NIH protocol 08-HG-0059
Subjects must have a diagnosis of atopic dermatitis on the basis of the criteria defined by UK Working Party s Diagnostic Criteria for Atopic Dermatitis
Subjects must have a primary care provider
Subjects must have an Objective SCORAD (SCORing Atopic Dermatitis) of greater than or equal to 15 indicating AD severity of moderate to severe
Prior to initiation of randomized treatment, subjects must have signs of bacterial skin infections (skin weeping, crusting, and/or pustules)
Access to bathing facilities
All subjects and/or their Legally Authorized Representative (LAR) must have the ability and agree to participate fully and comply with the procedures of the protocol and provide informed consent. Pediatric patients will be included in age appropriate discussions and age appropriate assent will be obtained in accordance with NIH guidelines. -Ability of subject to understand and provide written informed consent Cohort 6: Healthy Volunteers
Subjects previously enrolled in Cohorts 1 \[NO FURTHER ACCRUAL\] and 4 \[INACTIVE\] who completed on-protocol antibiotic regimen
Subjects must participate fully and be willing to comply with the procedures of the protocol
Ability of subject to understand and provide written informed consent

Exclusion Criteria

Cohorts 1 \[NO FURTHER ACCRUAL\] and 2 \[INACTIVE\]: Healthy Volunteers
Does not meet inclusion criteria
Any female with symptoms and/or serum hormone levels consistent with perimenopause or menopause
Use of systemic antibiotics in 12 months preceding baseline sampling
Use of swimming pools, hot tubs, or whirlpools in 7 days preceding baseline sampling
Use of topical or oral complementary/alternative medicine (CAM) agents within 4 weeks of initiation of treatment
Known allergic reaction to sulfa, beta-lactam, or tetracycline class drugs; or lidocaine or epinephrine
Family history of toxic epidermal necrolysis
Known allergy or sensitivity to sodium hypochlorite (NaOCl)
History of AD or asthma
Inability to comply with the requirements of the protocol
Pregnant or lactating
Subjects with a primary or acquired immunodeficiency, including HIV seropositiviy
Any chronic past or present medical illness, including chronic skin diseases like psoriasis
Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants
Subjects who provide direct healthcare or reside in healthcare facilities or in non-hospital settings such as, assisted living facilities, homeless shelters, jails and prisons as well as subjects with frequent exposure to laboratory animals Cohort 3 \[INACTIVE\]: Atopic Dermatitis Patients
Does not meet inclusion criteria
Any female with symptoms and/or serum hormone levels consistent with perimenopause or menopause
Known allergic reaction to beta-lactam class drugs, lidocaine, or epinephrine
Family history of toxic epidermal necrolysis
Known allergic reaction to sodium hypochlorite (NaOCl)
Use of systemic antibiotics within 8 weeks, or topical antibiotics on intended sampling sites within 3 weeks, prior to baseline sampling
Use of topical corticosteroids on all intended sampling sites within 7 days, prior to baseline sampling
Use of topical or oral CAM agents within 4 weeks of initiation of treatment
Subjects with known primary or acquired immunodeficiency
Subjects with unstable or uncontrolled medical conditions that could require hospitalization during the initial month of the study or who have been hospitalized for treatment of these conditions in the one month prior to baseline sampling
Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants within 7 days or 5 half-lives (whichever is the longer time period) of initiating treatment on this protocol
Subjects who are currently receiving or have received chemotherapy or radiation for treatment of malignancies within the previous 6 months
Pregnancy or lactating Cohorts 4 \[NO FURTHER ACCRUAL\] and 5 \[INACTIVE\]: Healthy Volunteers
Does not meet inclusion criteria
Any female with symptoms and/or serum hormone levels consistent with perimenopause or menopause
Use of systemic antibiotics in 12 months preceding baseline sampling
Use of swimming pools, hot tubs, or whirlpools in 7 days preceding baseline sampling
Use of topical or oral complementary/alternative medicine (CAM) agents within 4 weeks of initiation of treatment
(Cohort 4 \[NO FURTHER ACCRUAL\]) Known allergic reaction to sulfa class drugs; or lidocaine or epinephrine
(Cohort 5 \[INACTIVE\]) Known allergic reaction to tetracycline class drugs; or lidocaine or epinephrine
Family history of toxic epidermal necrolysis
History of AD or asthma
Inability to comply with the requirements of the protocol
Pregnant or lactating
Subjects with a primary or acquired immunodeficiency, including HIV seropositivity
Any chronic past or present medical illness, including chronic skin diseases like psoriasis
Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants
Subjects who provide direct healthcare or reside in healthcare facilities or in non-hospital settings such as assisted living facilities, homeless shelters, jails and prisons as well as subjects with frequent exposure to laboratory animals Cohort 6: Healthy Volunteers
Does not meet inclusion criteria
Use of swimming pools, hot tubs, or whirlpools in 7 days preceding sampling
Use of topical or oral CAM agents within 1 week or 4 weeks, respectively, prior to sampling
Pregnant or lactating females in all cohorts are excluded from participating due to the potential effects of the above listed antimicrobials on the developing human fetus or nursing infant; listed in Sections 11.1 through 11.5. Females of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Lactating mothers will discontinue breastfeeding prior to study enrollment.
Smokers and subjects who use smokeless tobacco products are excluded in all cohorts due to tobacco s unknown impact on human oral mucosa and microflora.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Bethesda?

Yes, this clinical trial (NCT01631617) has an active research site in Bethesda, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Eczema Treatment Options in Bethesda, MD

If you're searching for eczema treatment options in Bethesda, MD, this clinical trial (NCT01631617) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Bethesda research site is actively enrolling participants for this clinical trial. You'll receive care from experienced eczema specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all eczema clinical trials near you to find additional studies recruiting in your area.

More Atopic Dermatitis Trials in Bethesda, MD

See all atopic dermatitis clinical trials recruiting in Bethesda — not just this study.

Browse Atopic Dermatitis Trials in Bethesda →

Browse More Trials by Condition

Atopic Dermatitis TrialsAll Conditions →

Ready to Join in Bethesda?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Bethesda, MD